Fludarabine; melphalan; busulfan

Phase 2Small molecule

Fludarabine; melphalan; busulfan is one of 13 small molecule programs targeting Conditioning. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConditioningNot yet recruiting

ConditioningPhase 2

Not yet recruiting

Competition

Competitive Landscape

13 competitors in Conditioning

#DrugCompanyPhaseTrials

Fludara

Sanofi

Approved

7 2

Busulfex

Akero Therapeutics

Approved

15 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

17 4

Cellcept

Roche

Phase 3

2 5

Alkeran

AApotex Inc.

Phase 3

4 6

Jakafi

Incyte

Phase 2

2 7

Venclexta

AbbVie

Phase 2

1 8

Prograf

VVeloxis Pharmaceuticals

Phase 2

1 9

Cyclophosphamid

EEssen Biotech

Phase 2

1 10

Bendamustine Hydrochloride

SSymBio Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Conditioning

NCT07085156

Clinical

Trials by Indication[1]

Conditioning1 trial

Reduced Intensity Conditioning for MDS

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07085156·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fludarabine; melphalan; busulfan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludarabine; melphalan; busulfan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludarabine; melphalan; busulfan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRuijin Hospital

Fludarabine; melphalan; busulfan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Conditioning1 trial

References

Drug Info

Quick Facts

Related News